Celyad Oncology SA · EURONEXT:CYAD

Celyad Oncology SA — Fact Sheet (June 2022)

2 slides from Celyad Oncology SA's fact sheet, Jun 27, 2022

  1. Slide 1: KEYNOTE-B79 Phase 1b Trial with CYAD-101 and KEYTRUDA: Study Overview

    KEYNOTE-B79 Phase 1b Trial with CYAD‑101 and KEYTRUDA® STUDY OVERVIEW The KEYNOTE-B79 trial evaluates the safety and clinical activity of multiple infusions of CYAD-101, administered post FOLFOX preconditioning chemotherapy, followed by pembrolizumab treatment. The trial was initiated in the fourth

  2. Slide 2: CYAD-101 Overview and KEYNOTE-B79 Rationale

    KEYNOTE-B79 Phase 1b Trial with CYAD‑101 and KEYTRUDA® CYAD-101 OVERVIEW Off-the-shelf non-gene edited allogeneic CAR T Natural Killer Group 2D (NKG2D) receptor CAR Novel TCR Inhibitory Molecule (TIM) interferes with T cell receptor (TCR) complex TCR responsible for graft versus host disease (GvHD)c

Celyad Oncology — Fact Sheet (June 2022) on 6ix